Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Drug Development and Industrial Pharmacy|December 1, 2005
Reversible Z-E isomerism and pharmaceutical implications for SU5416Anand Sistla, Narmada ShenoyPDA Journal of Pharmaceutical Science and Technology|July 30, 2008
Development of an intravenous formulation of SU010382 (prodrug of SU5416, an anti-angiogenesis agent)Anand Sistla, Adriana Kertelj, Narmada ShenoyJournal of Chromatography. A|February 14, 2006
High-performance liquid chromatographic method for determination of reversible isomers of SU5416Anand Sistla, Wei-Lien Yang, Narmada ShenoyDrug Development and Industrial Pharmacy|March 6, 2004
Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trialsAnand Sistla, Alan Sunga, Kenneth Phung, et al.Blood|July 2, 2002
Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitorsAlbert T Liao, May B Chien, Narmada Shenoy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignanciesCheryl A London, Alison L Hannah, Regina Zadovoskaya, et al.Molecular Pharmacology|October 5, 2017
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune DiseaseRavi Jahagirdar, Sarah Attwell, Suzana Marusic, et al.Proceedings of the National Academy of Sciences of the United States of America|June 16, 2010
Insights into evolution of multicellular fungi from the assembled chromosomes of the mushroom Coprinopsis cinerea (Coprinus cinereus)Jason E Stajich, Sarah K Wilke, Dag Ahrén, et al.Nature Genetics|August 14, 2012
Lifestyle transitions in plant pathogenic Colletotrichum fungi deciphered by genome and transcriptome analysesRichard J O'Connell, Michael R Thon, Stéphane Hacquard, et al.Pageof 1